The most commonly used class of cancer immunotherapy is immune checkpoint inhibitors (ICI) including block cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed death-ligand 1 (PD-L1). Here, CTLA4 is linked to cancer.